PDMR Shareholding

RNS Number : 8816Q
Faron Pharmaceuticals Oy
05 December 2016
 

 

Faron Pharmaceuticals Oy
("Faron" or the "Company")

 

PDMR Shareholding

 

TURKU - FINLAND, 5 December 2016 - Faron Pharmaceuticals Ltd ("Faron") (LON: FARN), the clinical stage biopharmaceutical company, announces that on 16th and 19th September 2016 Dr Matti Karvonen, Medical Director of Faron, acquired ordinary shares in Faron on his own behalf and on behalf of his closely associated persons. As a member of the management group of Faron, Dr Karvonen is regarded as a person discharging managerial responsibility ("PDMR").    

 

PDMR                                                        Shares purchased

 

Matti Karvonen                                                        25,770

                                                                              25,770                                                              

 

The notification below, which has been made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

For more information please contact:

 

Faron Pharmaceuticals Ltd

Katja Wallenlind

Phone +358 (50) 577 4807
E-mail: katja.wallenlind@faronpharmaceuticals.com

 

Hume Brophy, PR

Mary Clark, Eva Haas, Hollie Vile

Phone: +44 207 862 6390

E-mail: faron@humebrophy.com

 

Cairn Financial Advisers LLP, Nominated Adviser

Emma Earl, Tony Rawlinson, Rebecca Anderson

Phone: +44 207 213 0880

 

Panmure Gordon (UK) Limited, Joint Broker

Freddy Crossley, Duncan Monteith (Corporate Finance)

Tom Salvesen (Corporate Broking)

Phone: +44 207 886 2500

 

Whitman Howard Limited, Nominated Broker

Ranald McGregor-Smith, Francis North

Phone: +44 207 659 1234

About Faron Pharmaceuticals Ltd

 

Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, cancer immunotherapy and vascular damage. The pipeline is built on Faron's scientific knowledge and control of the endothelial barrier, the membrane of cells lining blood and lymphatic vessels to separate blood content from tissues. The Company's lead candidate Traumakine® is in development for the treatment of Acute Respiratory Distress Syndrome ("ARDS"), a rare, severe, life-threatening medical condition characterised by widespread inflammation in the lungs. Traumakine is currently in pan-European (INTEREST) and Japanese pivotal Phase III studies. Additionally, Faron is developing Clevegen® a ground breaking pre-clinical anti-Clever-1 antibody. Clevegen has the ability to convert the immune environment around a tumour from being immune suppressive to immune stimulating. This novel macrophage-directed immuno-oncology approach is called Tumour Immunity Enabling Technology ("TIET") and can be used alone or in combination with other immune checkpoint molecules for the treatment of cancer patients. New application opportunities related to TIET cover chronic infections and inefficient vaccination. Based in Turku, Finland, Faron Pharmaceuticals is listed on AIM under the ticker 'FARN'. Further information is available at www.faronpharmaceuticals.com

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

1.    Matti Karvonen

                                                                                       

 

2

Reason for notification

 

 

 

a.

Position/Status

Person discharging managerial responsibilities

b.

Initial notification/

Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Faron Pharmaceuticals Oy

b.

LEI

7437009H31TO1DC0EB42

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Ordinary shares

ISIN: FI4000153309

 

b.

Nature of the transaction

Purchase of Ordinary Shares  

c.

Price(s) and volume(s)

 

 

 

 

 

 

Price(s)

Volume(s)

 

1.    3.04€

 

16,770

 

 

 

 

 

d.

Aggregated information

 

- Aggregated Volume

 

- Price

 

 

N/a (Single transaction)

e.

Date of the transaction

16 September 2016

f.

Place of the transaction

Turku

 

                 

 

 

a.

Description of the financial instrument, type of instrument

Identification Code

Ordinary shares

ISIN: FI4000153309

 

b.

Nature of the transaction

Purchase of Ordinary Shares

c.

Price(s) and volume(s)

 

 

 

 

 

 

Price(s)

Volume(s)

 

1.     €2.78

9,000

 

 

 

d.

Aggregated information

 

- Aggregated Volume

 

- Price

 

 

N/a (Single transaction)

e.

Date of the transaction

19 September 2016

f.

Place of the transaction

Turku

 

                 

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHFSEFWEFMSEEE
UK 100

Latest directors dealings